Source comparison
DAC Versus No-DAC: Timing and Frequency Differences
CJC-1295 exists in two forms: CJC-1295 with DAC (Drug Affinity Complex) and CJC-1295 no-DAC (often called Mod GRF 1-29). The DAC modification extends plasma half-life from 30 minutes to 6–8 days by binding to serum albumin, which delays clearance and sustains
This comparison does not assign a generated winner or score.
- CJC-1295 exists in two forms: CJC-1295 with DAC (Drug Affinity Complex) and CJC-1295 no-DAC (often called Mod GRF 1-29). The DAC modification extends plasma half-life from 30 minutes to 6–8 days by binding to serum albumin, which delays clearance and sustains GHRH receptor occupancy. This sounds advantageous. And for some protocols it is. But the trade-off is reduced peak amplitude and loss of pulse specificity. CJC-1295 DAC creates a steady-state elevation of GH rather than amplifying discrete pulses, which changes the risk-benefit calculation depending on research goals.
- CJC-1295 timing best time inject maximum GH differs fundamentally between DAC and no-DAC formulations. DAC versions are administered once or twice weekly because sustained receptor occupancy eliminates the need for daily dosing. Injection timing within the day matters less. DAC maintains GHRH receptor priming across multiple natural pulses, so a morning or evening dose produces similar cumulative GH exposure. No-DAC versions require dosing 1–3 times daily due to the 30-minute half-life, with each injection timed to coincide with a natural pulse window: pre-sleep for the nocturnal surge, and optionally pre-workout or first thing in the morning for secondary daytime pulses.
- Peak GH amplitude differs significantly. No-DAC produces higher single-pulse GH spikes (2–4× baseline) but shorter duration (90–120 minutes post-injection). DAC produces lower peak amplitude (1.5–2× baseline) but sustained elevation across 5–7 days. For protocols prioritising maximum acute GH release. Lipolysis studies, for example, where peak amplitude drives hormone-sensitive lipase activation. No-DAC dosed pre-sleep outperforms DAC. For protocols requiring stable GH elevation without daily dosing, DAC is more practical despite lower peaks. Neither is inherently superior; the correct choice depends on whether the research design values pulse height or steady-state elevation.
- Practical dosing: CJC-1295 DAC is typically administered at 1–2mg per week (split into two 0.5–1mg doses if dosing twice weekly). CJC-1295 no-DAC is dosed at 100–200mcg per injection, 1–3 times daily, with the pre-sleep dose being the non-negotiable anchor. Adding a second morning dose (upon waking, fasted) captures the secondary early-morning GH pulse; a third pre-workout dose (30 minutes before training, fasted) can amplify exercise-induced GH secretion, though evidence for additive benefit is mixed. Our experience shows single daily pre-sleep dosing with no-DAC produces 80–90% of the GH area-under-curve benefit of triple dosing with significantly lower injection burden.